^
Association details:
| Biomarker: | Chr del(11q) |
|---|---|
| Cancer: | Chronic Lymphocytic Leukemia |
| Drug: | Rituxan (rituximab) (CD20 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Excerpt:
Outcomes for CLL with del(11q) are better with chemoimmunotherapy containing an alkylating agent. Therefore, FR is not recommended for CLL with del(11q).
Secondary therapy:
fludarabine oral
Source:
Title:
MABTENANCE: International, Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment versus Observation alone in Patients with Chronic Lymphocytic Leukemia
Excerpt:
...- MRD-progression free survival- PFS and MRD PFS in relation to gender - conversion rate to MRD negative- median MRD levels- conversion rate to CR- effect of MRD levels on clinical PFS and OS- Event free survival- Time to next treatment- overall survival- safety- benefit according to cytogenetic risk group (trisomy 12, del 11q, del 17p and del 13q ), IgVH mutation status, ZAP 70 and CD38 expression`- MRD-progression free survival - PFS and MRD PFS in relation to gender - conversion rate to MRD negative - median MRD levels - conversion rate to CR - effect of MRD levels on clinical PFS and OS - Event free survival - Time to next treatment - overall survival - safety - benefit according to cytogenetic risk group (trisomy 12, del 11q, del 17p and del 13q ), IgVH mutation status, ZAP 70 and CD38 expression`MRD-progression free survival conversion rate to MRD negative median MRD levels conversion rate to CR effect of MRD levels on clinical PFS and OS event free survival time to next treatment OS safety benefit according to cytogenetic risk groups...
Trial ID:
Source:
Title:
Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
Excerpt:
...MRD (minimal residual disease) progression free survival`conversion rate to MRD negative`median MRD levels`conversation rate to CR`effect of MRD levels on clinical PFS and OS`event free survival`time to next treatment`overall survival`Safety of Rituximab maintenance treatment in patients with CLL`benefit according to cytogenetic risk group (trisomy 12, del 11q, del 17p and del 13q), IgVH mutation status, ZAP 70 and CD38 expression...
Trial ID:
More C2 evidence
Source:
Title:
Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and Rituximab
Excerpt:
...- Poor-risk small lymphocytic lymphoma or chronic lymphocytic leukemia, defined by a 17p deletion, 11q deletion, or histologic conversion (if histologic conversion, PR or CR is required)...
Trial ID:
Source:
Title:
Phase II Study of High-Dose Rituximab in High-Risk Chronic Lymphocytic Leukemia Patients in Suboptimal Response After Induction Immunochemotherapy
Excerpt:
...- POOR PROGNOSTIC FEATURES (before induction ICT) defined by at least one of the following markers: stage C Binet, unmutated IgVH genes, 17p deletion, 11q deletion, Zap-70 positivity, high CD38, mutated IgVH genes if VH3-21 usage...
Trial ID:
Source:
Title:
Cyclophosphamide and Rituximab Followed By Vaccine Therapy in Treating Patients With Chronic Lymphocytic Leukemia
Excerpt:
...- 11q deletion by FISH...
Trial ID:
Source:
Title:
High-dose Methylprednisolone and Rituximab in High Risk B-CLL
Excerpt:
...- 11q del confirmed by FISH or...
Trial ID:
